Breakthrough Health (MS Platform)
Digital health platform for multiple sclerosis patients
Platform · Cloud SaaSCompany source
Company profile
About Mymee
Mymee is a digital therapeutics company that has developed the first clinically validated platform for identifying and managing autoimmune disease triggers through personalized environmental analysis. The company's proprietary method helps patients with rheumatoid arthritis, lupus, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, long COVID, and other autoimmune conditions discover hidden triggers in their exposome—the environmental factors that influence disease flares. The platform combines a custom mobile app, proprietary data analytics, and weekly one-on-one sessions with specialized health coaches to correlate symptoms with environmental triggers. Clinical studies have demonstrated that Mymee's approach achieves a mean reduction of over 40% in moderate to high-frequency symptoms, with more than 70% of patients reversing their health-related quality of life severity from moderate-to-severe to mild-to-normal as measured by PROMIS. The solution empowers patients to gain control over their autoimmune conditions in an average of 17 weeks through personalized trials that identify unique sensitivities to diet, lifestyle, and environmental factors. Mymee's coach-led platform also provides medication tapering support based on genetics, personal preferences, and health needs, working in accordance with physician and pharmacist-recommended drug regimens. The company serves patients who are non-responders to standard therapies and those seeking to reduce reliance on medications through evidence-based lifestyle interventions.
Company description Mymee official website
Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Mymee?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Ankylosing Spondylitis
- Celiac Disease
- Crohn's Disease
- IBD
- Long COVID
- Lupus
- Mixed Connective Tissue Disorder
- Multiple Sclerosis
- Myasthenia Gravis
- Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Sjogren's Syndrome
Who it serves
- Consumers
- Payers
- Physicians
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Acquired Breakthrough Health, a leading digital health platform for multiple sclerosis
Partnerships
Recorded partners
- Breakthrough Health (acquired)
- Johnson & Johnson (External Innovation & New Business Models)
- Oscar Health (former Population Health leadership endorsement)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Mymee Personalized Trial & Care Platform
Digital care solution to identify autoimmune disease triggers and reduce flares
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Self-evidence-based digital care programme improves health-related quality of life in adults with a variety of autoimmune diseases and long COVID: a retrospective study.RMD open · May 1, 2023
A mobile health + health coaching application for the management of chronic non-cancer pain in older adults: Results from a pilot randomized controlled study.Frontiers in pain research (Lausanne, Switzerland) · Jan 1, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
>40% mean reduction in 59 moderate to high-frequency symptoms
Autoimmune patients using Mymee platform
>70% of patients reversed HRQoL severity level from moderate-to-severe to mild-to-normal
As measured by PROMIS
Average 17 weeks to significantly improve health
Time to identify triggers and achieve symptom improvement
Christina (Myasthenia Gravis Patient)
Managing chronic fatigue from myasthenia gravis
First time in memory going days without naps or feeling tired
Clinical Validation Study
Reducing moderate to high-frequency autoimmune symptoms across multiple conditions
>40% mean reduction in 59 moderate to high-frequency symptoms; >70% of patients reversed HRQoL severity from moderate-to-severe to mild-to-normal (PROMIS)
Debi (Ankylosing Spondylitis Patient)
Managing ankylosing spondylitis symptoms and reducing shoulder pain
Eliminated shoulder pain when putting on and taking off shirt
Janelle (Rheumatoid Arthritis Patient)
Managing rheumatoid arthritis pain and identifying personal triggers
Pain reduced from 'walking on glass' to returning to full work schedule during NY Fashion Week by week 7
Jasper (Multiple Sclerosis Patient)
Managing excruciating MS pain and improving quality of life
Transitioned from excruciating pain to huge sense of relief
Lori (Long COVID Patient)
Managing and recovering from long COVID symptoms
Gradually and effectively got symptoms under control
Sally (Psoriatic Arthritis Patient)
Managing psoriatic arthritis symptoms including body pain, nausea, and dysphagia
Significant improvement by session 7, no longer experiencing body pain, nausea, and dysphagia
Sam (Psoriasis Patient)
Managing psoriasis and overcoming hopelessness
Moved from feeling hopeless to excited about daily activities and social engagement
Tracey (Lupus Patient)
Understanding and managing lupus flare triggers
Gained control over lupus flares with personal data to share with doctor
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Mymee
Recent articles published on Mymee's official website.
Mymee’s Personalized Trial & Care Platform Helps Autoimmune Disease Patients Reverse Flares, New Research Shows
Read on MymeeMymee Acquires Breakthrough Health, Leading Digital Health Platform for Multiple Sclerosis
Read on MymeeVideo: An Evening With Meghan O’Rourke
Read on MymeeRecognizing Multiple Sclerosis: An MS Symptoms Checklist
Read on MymeeWhat are the Symptoms of Celiac Disease?
Read on Mymee07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.